UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

January 7, 2013

________________

NOVO NORDISK A/S(Exact name of Registrant as specified in its charter)

Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [X]           Form 40-F [  ]

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [  ]            No [X]

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________

 

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 7 January 2013 – On 9 November 2012 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 1.5 billion in the period from 9 November 2012 to 29 January 2013.

Since the announcement as of 2 January 2013, the following transactions have been made under the programme:

	Number of shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	543,957		499,999,588
2 January 2013	50,000	930.27	46,513,340
3 January 2013	54,666	936.80	51,211,377
4 January 2013	54,848	945.61	51,864,993
Accumulated under the programme	703,471		649,589,297

With the transactions stated above, Novo Nordisk owns a total of 17,576,190 treasury shares, corresponding to 3.1% of the share capital. The total amount of shares in the company is 560,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares worth DKK 12.0 billion during a 12 month period beginning 2 February 2012. As of 4 January 2013, Novo Nordisk has repurchased a total of 13,216,931 B shares equal to a transaction value of DKK 11,149,588,608.

Novo Nordisk A/S	Novo Allé	Telephone:		Internet:
Investor Relations	2880 Bagsværd	+45 4444 8888		www.novonordisk.com
	Denmark	Telefax:		CVR no:
		+45 4444 6626		24 25 67 90
			Company announcement No 3 / 2013

Page 2 of 2

Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 33,900 employees in 75 countries, and markets its products in more than 190 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com. 

Further information
Media:
Anne Margrethe Hauge	+45 4442 3450	amhg@novonordisk.com
Ken Inchausti (US)	+1 609 514 8316	kiau@novonordisk.com
Investors:
Kasper Roseeuw Poulsen	+45 4442 4303	krop@novonordisk.com
Frank Daniel Mersebach	+45 4442 0604	fdni@novonordisk.com
Lars Borup Jacobsen	+45 3075 3479	lbpj@novonordisk.com
Jannick Lindegaard (US)	+1 609 786 4575	jlis@novonordisk.com

Novo Nordisk A/S	Novo Allé	Telephone:		Internet:
Investor Relations	2880 Bagsværd	+45 4444 8888		www.novonordisk.com
	Denmark	Telefax:		CVR no:
		+45 4444 6626		24 25 67 90
			Company announcement No 3 / 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: January 7, 2013 NOVO NORDISK A/S Lars Rebien Sørensen, President and Chief Executive Officer